Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Searle CoKAR:SEARL +1.09%71 EV-to-EBIT is 8.94 as of Sep. 13, 2026, which is 31% below its 10-year median of 13.01. GuruFocus rates KAR:SEARL with a GF Score™ of 71/100 and a GF Value™ of ₨75.08 (Fairly Valued). The stock has 3 warning signs investors should review. Among 683 Drug Manufacturers companies, The Searle Co ranks better than 75.99% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
The Searle Co's Enterprise Value for the quarter that ended in Mar. 2026 was ₨55,700 Mil.
The Searle Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨6,155 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Searle Co EV-to-EBIT Related Terms
The Searle Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for The Searle Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Searle Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Searle Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where The Searle Co's EV-to-EBIT falls into.
The Searle Co's current Enterprise Value is ₨55,035 Mil.
The Searle Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨6,155 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Searle Co (KAR:SEARL) has a EV-to-EBIT of 8.94 as of Sep. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on The Searle Co and its competitors. This is 31% below median its historical median of 13.01. Over the past decade, The Searle Co's EV-to-EBIT has ranged from 7.17 to 36.93. According to the industry distribution chart, The Searle Co ranks #164 out of 683 companies in the Drug Manufacturers industry, placing it in the top 24%.
Is The Searle Co's EV-to-EBIT too high?
The Searle Co's current EV-to-EBIT of 8.94 is 31% below median its 10-year median of 13.01. Over the past 10 years, this metric has ranged from a low of 7.17 to a high of 36.93. The Drug Manufacturers industry median EV-to-EBIT is 16.13. The Searle Co's value of 8.94 is 44.6% below this industry median. Based on the distribution chart, The Searle Co ranks #164 out of 683 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, The Searle Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does The Searle Co's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, The Searle Co ranks #164 out of 683 companies for EV-to-EBIT. This places The Searle Co in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.13. The Searle Co's value of 8.94 is 44.6% below this benchmark. Historically, The Searle Co's own EV-to-EBIT has ranged from 7.17 to 36.93 over the past decade. While the company's 10-year median is 13.01 vs. the industry median of 16.13, The Searle Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.13, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Searle Co's current EV-to-EBIT of 8.94 is 44.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on The Searle Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Searle Co's current EV-to-EBIT is 8.94, which is 31% below median its own 10-year median of 13.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Searle Co stock overvalued right now?
Based on GuruFocus' analysis, The Searle Co (KAR:SEARL) is currently considered Fairly Valued. The stock's GF Value™ is ₨75.08, compared to a current price of ₨79.91 — trading 6.4% above its estimated fair value. The current EV-to-EBIT is 8.94, which is 31% below median its 10-year median of 13.01 and 44.6% below the Drug Manufacturers industry median of 16.13. The Searle Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For The Searle Co (KAR:SEARL), the current EV-to-EBIT is 8.94 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Searle Co (KAR:SEARL) Overvalued in 2026?
Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued.
The current stock price of ₨79.91 is trading 6.4% above its estimated GF Value™ of ₨75.08.
GuruFocus considers The Searle Co to be Fairly Valued.
Key valuation signals for KAR:SEARL:
EV-to-EBIT: 8.94 (31% below median its 10-year median of 13.01)
GF Value™: ₨75.08 vs. price of ₨79.91 (6.4% above fair value)
Industry Position: 44.6% below the Drug Manufacturers median (#164 of 683)
No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
71GF Score
Get the complete analysis for KAR:SEARL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:SEARL has been successfully added to your 
